Chronic Total Occlusion Crossing With the Wildcat Catheter

Overview

This is a prospective, multi-center, non-randomized study of the Wildcat Catheter to cross a single femoropopliteal chronic total occlusion (CTO). Safety and efficacy will be evaluated during the index procedure through 30-day follow-up.

Full Title of Study: “A Non-randomized Study of the Avinger Wildcat Used to Cross Femoropopliteal CTOs”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2011

Detailed Description

Patients with a CTO, defined as 99% to 100% stenosis of a peripheral artery, will be approached for enrollment in the study. Following providing informed consent, the CTO will be addressed by the Wildcat catheter, which will provide a route for the advancement of guidewires and other tools beyond the CTO. Data will be collected to assess the safety efficacy of use of the device during the procedure and up to 30 days post-procedure.

Interventions

  • Device: Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
    • A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries

Arms, Groups and Cohorts

  • Experimental: Treatment
    • The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.

Clinical Trial Outcome Measures

Primary Measures

  • Major Adverse Events
    • Time Frame: Index through 30-Day Follow-Up
    • The primary safety endpoint of the CONNECT Study was defined as absence of in-hospital or 30-days Major Adverse Events (MAEs), no evidence of clinically significant perforations, clinically significant embolizations or Grade C or greater dissections after Wildcat CTO crossing confirmed by angiography.
  • CTO Crossing Success Using the Wildcat
    • Time Frame: Index through 30-Day Follow-Up
    • Successful femoropopliteal CTO crossing using the Wildcat identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography.

Participating in This Clinical Trial

Inclusion Criteria

1. Patient is willing and able to provide informed consent. 2. Patient is willing and able to comply with the study protocol. 3. Patient is > 18 years old. 4. Patient has peripheral arterial disease requiring revascularization as evidenced by contrast, CT or MR angiography. 5. Patient has an occluded femoropopliteal artery that is 99-100% stenosed and is ≥ 1 cm and ≤ 30 cm in length by visual estimate. 6. Target femoropopliteal vessel is ≥ 3.0 mm in diameter. 7. Patient has Rutherford Classification of 2-5. Exclusion Criteria:

1. Patient has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated. 2. Patient has a known sensitivity or allergy to anti-platelet medications. 3. Patient is pregnant or lactating. 4. Patient has a co-existing disease or medical condition contraindicating percutaneous intervention. 5. Target vessel is severely calcified as evidenced by angiography. 6. Target lesion is in a bypass graft. 7. Target lesion is in a stent (i.e., in-stent restenosis). 8. Patient has had a procedure on the target limb within 7 days. 9. Patient has had a procedure on the target limb within the past 30 days and is unstable. 10. Patient is simultaneously participating in an investigational device or drug study. 11. Patient has a planned surgical or interventional procedure within 30 days after the study procedure.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Avinger, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tom Davis, MD, Principal Investigator, St. John Hospital
    • Laiq Raja, MD, Principal Investigator, El Paso Cardiology Associates

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.